Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012†...
Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") today announced financial results for the third quarter and nine-month period ended September 30, 2024. Highlights ...
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell ...
Abivax presents third quarter 2024 key financial information. PARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – AB ...
Abivax presents third quarter 2024 key financial informationPARIS, France, November 14, 2024, 10:00 p.m. CET – Abivax SA (Euronext Paris: ...
Good morning and welcome to ImmuCell Corporation Reports Third Quarter September 30, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode. After today’s ...
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commerciali ...
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback